Ticker HubNasdaq

ATYR

aTyr Pharma, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Latest regular mover

Latest price

$6.05+22.37%

As of Nov 2, 2026, 2:52 PM EST · Market data by Massive

Market cap

$12.4M

Volume

314.2K

Previous close

$4.94

Day range

$5.03 – $6.42

Listed

May 7, 2015

Coverage

1 article

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $5.93Latest interval $6.05

Newsroom

Latest ATYR coverage

Nov 2, 2026

Midday Movers: INO, CLRO, INLF Lead the Small-Cap Scan

INO led a group of 10 active small-cap stocks flagged for editorial review.

INOCLROINLFEVGO

Recent catalyst headlines

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

Oct 29, 2026

aTyr Pharma Announces One-for-40 Reverse Stock Split

Oct 27, 2026

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

Oct 19, 2026

Company overview

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 58
Headquarters: SAN DIEGO, CA
CIK: 0001339970

Company website View advanced chart

SEC filings

8-K

SCHEDULE 13G/A

SCHEDULE 13G/A filing

8-K

DEF 14A

PRE 14A

Browse EDGAR

Profile at a glance

May 7, 2015

Listed

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.